Kyntra Bio, Inc.
NASDAQ Global MarketTotal Valuation
Kyntra Bio, Inc. carries a market capitalization of 34.61M, placing it among publicly traded companies globally. Its enterprise value stands at -25.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 34.61M |
| Enterprise Value | -25.28M |
Share Statistics
Kyntra Bio, Inc. currently has 4.05M shares outstanding.
| Shares Outstanding | 4.05M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Kyntra Bio, Inc. trades at a trailing price-to-earnings ratio of 0.17. The price-to-sales ratio is 3.69, and the price-to-book ratio stands at -0.63.
| PE Ratio | 0.17 |
| PS Ratio | 3.69 |
| PB Ratio | -0.63 |
| P/TBV Ratio | -0.63 |
| P/FCF Ratio | -1.28 |
| P/OCF Ratio | -1.28 |
Financial Position
Kyntra Bio, Inc. maintains a current ratio of 3.61, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.61 |
| Quick Ratio | 3.42 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -4.92 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 119.06 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.35 |
Taxes
| Income Tax | -92,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Kyntra Bio, Inc.'s stock has declined approximately -24.40318% over the past 52 weeks. The 50-day moving average sits at 7.34, while the 200-day moving average is 7.59.
| Beta (5Y) | N/A |
| 52-Week Price Change | -24.40318% |
| 50-Day Moving Average | 7.34 |
| 200-Day Moving Average | 7.59 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Kyntra Bio, Inc. generated 7.44M in revenue and converted that into 163.62M in net income, yielding earnings per share of -13.99. EBITDA reached -43.92M, while operating income came in at -44.34M.
| Revenue | 7.44M |
| Gross Profit | 3.03M |
| Operating Income | -44.34M |
| Pretax Income | -56.66M |
| Net Income | 163.62M |
| EBITDA | -43.92M |
| EBIT | -44.34M |
| Earnings Per Share (EPS) | -13.99 |
Balance Sheet
Total book value stands at -43.80M, with working capital of 73.24M providing operational flexibility.
| Cash & Cash Equivalents | 87.24M |
| Total Debt | N/A |
| Net Debt | -37.00M |
| Equity (Book Value) | -43.80M |
| Book Value Per Share | -10.82 |
| Working Capital | 73.24M |
Cash Flow
Kyntra Bio, Inc. produced -21.38M in operating cash flow over the past twelve months. After subtracting -22,000.00 in capital expenditures, free cash flow totaled -21.40M - equivalent to -5.29 per share.
| Operating Cash Flow | -21.38M |
| Capital Expenditures | -22,000.00 |
| Free Cash Flow | -21.40M |
| FCF Per Share | -5.29 |
Margins
Kyntra Bio, Inc. operates with a gross margin of 40.70, reflecting its pricing power and cost economics. The operating margin of -596.10 and net profit margin of 2,199.42 provide insight into operational efficiency.
| Gross Margin | 40.70 |
| Operating Margin | -596.10 |
| Pretax Margin | -761.70 |
| Profit Margin | 2,199.42 |
| EBITDA Margin | -590.35 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 313.15 |
| FCF Yield | -77.88 |
Stock Splits
Kyntra Bio, Inc.'s most recent stock split took place on June 17, 2025 with a 25:1 split ratio.
| Last Split Date | 6/17/2025 |
| Split Ratio | 25:1 |
Scores
Kyntra Bio, Inc. posts an Altman Z-Score of -22.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -22.31 |